Literature DB >> 26941448

ABC3 Consensus Commented from the Perspective of the German Guidelines: Third International Consensus Conference for Advanced Breast Cancer (ABC3), Lisbon, 07. 11. 2015.

M Untch1, D Augustin2, J Ettl3, R Haidinger4, N Harbeck5, H-J Lück6, D Lüftner7, F Marmé8, L Müller9, F Overkamp10, E Ruckhäberle11, M Thill12, C Thomssen13, R Wuerstlein14, N Marschner15.   

Abstract

The Third International Consensus Conference for Advanced Breast Cancer ABC3 on the diagnosis and treatment of advanced breast cancer was held in Lisbon from 5 to 7 November 2015. This year the focus was the treatment of metastatic breast cancer (stage IV) - including the patient perspectives. Important topics were questions relating to quality of life, the care for long-term survivors as well as the management of disease-related symptoms and treatment-based side effects. The use of standardised tools to assess individual treatment success and the benefits of new substances were important points for discussion. The diagnosis and treatment of inoperable locally advanced breast cancer were discussed two years ago during the ABC2 consensus 1. A working group of German breast cancer experts commented on the results of the ABC panellists, paying particular attention to the German guidelines (AGO, S3, DGHO) on the diagnosis and treatment of breast cancer 2, 3, 4, 5 in Germany.

Entities:  

Keywords:  ABC3 Consensus; Guidelines; Metastatic breast cancer; System therapy

Year:  2016        PMID： 26941448      PMCID： PMC4771501          DOI： 10.1055/s-0042-101168

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN： 0016-5751            Impact factor:   2.915


  12 in total

1.  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.

Authors:  José Baselga; Mario Campone; Martine Piccart; Howard A Burris; Hope S Rugo; Tarek Sahmoud; Shinzaburo Noguchi; Michael Gnant; Kathleen I Pritchard; Fabienne Lebrun; J Thaddeus Beck; Yoshinori Ito; Denise Yardley; Ines Deleu; Alejandra Perez; Thomas Bachelot; Luc Vittori; Zhiying Xu; Pabak Mukhopadhyay; David Lebwohl; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2011-12-07       Impact factor: 91.245

2.  AGO Recommendations for the Diagnosis and Treatment of Patients with Advanced and Metastatic Breast Cancer: Update 2015.

Authors:  Cornelia Liedtke; Marc Thill; Volker Hanf; Florian Schuütz
Journal:  Breast Care (Basel)       Date:  2015-06-18       Impact factor: 2.860

3.  American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.

Authors:  Lowell E Schnipper; Nancy E Davidson; Dana S Wollins; Courtney Tyne; Douglas W Blayney; Diane Blum; Adam P Dicker; Patricia A Ganz; J Russell Hoverman; Robert Langdon; Gary H Lyman; Neal J Meropol; Therese Mulvey; Lee Newcomer; Jeffrey Peppercorn; Blase Polite; Derek Raghavan; Gregory Rossi; Leonard Saltz; Deborah Schrag; Thomas J Smith; Peter P Yu; Clifford A Hudis; Richard L Schilsky
Journal:  J Clin Oncol       Date:  2015-06-22       Impact factor: 44.544

4.  A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

Authors:  N I Cherny; R Sullivan; U Dafni; J M Kerst; A Sobrero; C Zielinski; E G E de Vries; M J Piccart
Journal:  Ann Oncol       Date:  2015-05-30       Impact factor: 32.976

5.  Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.

Authors:  Nicholas C Turner; Jungsil Ro; Fabrice André; Sherene Loi; Sunil Verma; Hiroji Iwata; Nadia Harbeck; Sibylle Loibl; Cynthia Huang Bartlett; Ke Zhang; Carla Giorgetti; Sophia Randolph; Maria Koehler; Massimo Cristofanilli
Journal:  N Engl J Med       Date:  2015-06-01       Impact factor: 91.245

6.  FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer.

Authors:  Jonas Bergh; Per-Ebbe Jönsson; Elisabet Kerstin Lidbrink; Maureen Trudeau; Wolfgang Eiermann; Daniel Brattström; Justin P O Lindemann; Fredrik Wiklund; Roger Henriksson
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

7.  Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.

Authors:  J G Klijn; R W Blamey; F Boccardo; T Tominaga; L Duchateau; R Sylvester
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

8.  Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors:  Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal:  N Engl J Med       Date:  2012-10-01       Impact factor: 91.245

9.  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study.

Authors:  Kimberly L Blackwell; Harold J Burstein; Anna Maria Storniolo; Hope S Rugo; George Sledge; Gursel Aktan; Catherine Ellis; Allison Florance; Svetislava Vukelja; Joachim Bischoff; José Baselga; Joyce O'Shaughnessy
Journal:  J Clin Oncol       Date:  2012-06-11       Impact factor: 44.544

10.  Combination anastrozole and fulvestrant in metastatic breast cancer.

Authors:  Rita S Mehta; William E Barlow; Kathy S Albain; Ted A Vandenberg; Shaker R Dakhil; Nagendra R Tirumali; Danika L Lew; Daniel F Hayes; Julie R Gralow; Robert B Livingston; Gabriel N Hortobagyi
Journal:  N Engl J Med       Date:  2012-08-02       Impact factor: 91.245
View more
  6 in total

1.  Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.

Authors:  Nirmesh Patel; Daniel Weekes; Konstantinos Drosopoulos; Patrycja Gazinska; Elodie Noel; Mamun Rashid; Hasan Mirza; Jelmar Quist; Fara Brasó-Maristany; Sumi Mathew; Riccardo Ferro; Ana Mendes Pereira; Cynthia Prince; Farzana Noor; Erika Francesch-Domenech; Rebecca Marlow; Emanuele de Rinaldis; Anita Grigoriadis; Spiros Linardopoulos; Pierfrancesco Marra; Andrew N J Tutt
Journal:  Nat Commun       Date:  2018-03-13       Impact factor: 14.919

Review 2.  Review of concepts in therapeutic decision-making in HER2-negative luminal metastatic breast cancer.

Authors:  I Alvarez-Lopez; S Bezares; E Dalmau Portulas; E García-Martínez; J Á García-Sáenz; M Gil-Gil; E Martínez de Dueñas; N Ribelles; A Santaballa Bertrán
Journal:  Clin Transl Oncol       Date:  2020-02-12       Impact factor: 3.405

3.  Aggressive Local Treatment Improves Survival in Stage IV Breast Cancer With Synchronous Metastasis.

Authors:  Chen-Lu Lian; Li-Yi Guo; Lei Zhang; Jun Wang; Jian Lei; Li Hua; Zhen-Yu He; San-Gang Wu
Journal:  Front Oncol       Date:  2020-11-16       Impact factor: 6.244

4.  Additional radiotherapy to breast-conserving surgery is an optional treatment for de novo stage IV breast cancer: A population-based analysis.

Authors:  Jun Wang; Shi-Ping Yang; Ping Zhou; Chen-Lu Lian; Jian Lei; Li Hua; Zhen-Yu He; San-Gang Wu
Journal:  Cancer Med       Date:  2021-02-14       Impact factor: 4.452

5.  Efficacy and safety of low-dose everolimus combined with endocrine drugs for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer.

Authors:  Hui-Qiang Zhang; Jin-Mei Zhou; Shao-Hua Zhang; Li Bian; Jin-Yi Xiao; Xiao-Peng Hao; Ze-Fei Jiang; Tao Wang
Journal:  Ann Transl Med       Date:  2021-10

6.  Surgery of the primary tumor improves survival in women with stage IV breast cancer in Southwest China: A retrospective analysis.

Authors:  Yuxin Xie; Xingxing Lv; Chuanxu Luo; Kejia Hu; Qiheng Gou; Keqi Xie; Hong Zheng
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.